Medtronic to Acquire Nutrino Health
November 21, 2018
(GLOBE NEWSWIRE via COMTEX) --Acquisition to Augment Diabetes Capabilities with Nutritional Database and Data Science
DUBLIN and TEL AVIV, Israel - November 21, 2018 - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Nutrino Health Ltd., a leading provider of nutrition-related data services, analytics, and technologies, today announced the companies have entered into a definitive agreement under which Medtronic will acquire Nutrino. Given that food and nutrition are central components in effective diabetes management, the companies recognized an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and artificial intelligence (AI)-driven personalized insights with Medtronic's technology and future innovations.
Medtronic Launches Patient Engagement Program That Leverages Gamification to Help Motivate and Engage Patients Living with Diabetes
August 9, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - August 9, 2018 - Medtronic today announced the official U.S. launch of the Medtronic Inner CircleSM patient engagement program, which uses gamification - the application of game design elements - to motivate and encourage people living with diabetes to achieve better health outcomes.
Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers
June 28, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN- June 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the MiniMed(TM) 670G Performance Guarantee Program - an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
Medtronic Receives CE Mark for MiniMed(TM) 670G Hybrid Closed Loop System
June 25, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 25, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system - the first and only system to automate and personalize the delivery of basal insulin 24 hours a day1. The system is CE Mark approved for the treatment of people with type 1 diabetes 7 years of age and older with ongoing studies to expand the indication to additional patient populations.
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
June 24, 2018
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 24, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 million patient days showed an average Time in Range of 70.6 percent across all age groups for those using the system's most advanced SmartGuard(TM) technology - the only smart algorithm that can adapt to fluctuating glucose levels and automatically self-adjust background insulin delivery. This advanced algorithm mimics some of the functions of a healthy pancreas and is the only technology in the world that proactively drives increased Time in Range - addressing both highs and lows.
For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:
For all other media inquiries please select the appropriate Global Public and Media Relations contact